Bevacizumab treatment for subfoveal choroidal neovascularization from causes other than age-related macular degeneration.

Abstract

OBJECTIVE:

To report the results of intravitreous bevacizumab (Avastin) treatment for choroidal neovascularization (CNV) from causes other than age-related macular degeneration (AMD).

METHODS:

We performed a retrospective analysis of eyes that received intravitreous bevacizumab, 1.25 mg, for subfoveal non-AMD CNV at a referral-based retinal practice. Repeated treatment with intravitreous bevacizumab occurred if there were signs of persistent or recurrent exudation. The main outcome measure was visual acuity (VA).

RESULTS:

The study included 39 eyes of 36 patients with subfoveal CNV secondary to multifocal choroiditis (n = 12), angioid streaks (n = 11), myopic degeneration (n = 10), idiopathic disease (n = 4), or other disease (n = 2). The median baseline VA was 20/60 (logMAR, 0.48). The mean follow-up was 58.8 weeks, and the mean number of injections per eye was 3.4. After 3-month follow-up, the median VA was 20/30 (logMAR, 0.18) (P = .004 vs baseline). At last follow-up, the median VA was 20/40 (logMAR, 0.30). This remained an improvement compared with baseline (P < .02) but was worse than 3-month follow-up (P < .03). There was no correlation between underlying diagnosis and VA change during follow-up.

CONCLUSION:

Subfoveal CNV secondary to non-AMD causes treated with intravitreous bevacizumab responded favorably and similarly, despite varying underlying etiologies.

• Authors: Louis K Chang, Richard F Spaide, Claudia Brue, K Bailey Freund, James M Klancnik Jr, Jason S Slakter
• Journal: Archives of ophthalmology (Chicago, Ill. : 1960) (Arch Ophthalmol) Vol. 126 Issue 7 Pg. 941-5 (Jul 2008) ISSN: 1538-3601 [Electronic] United States
• PMID: 18625940 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Angiogenesis Inhibitors
• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Vascular Endothelial Growth Factor A
• Bevacizumab
• Triamcinolone Acetonide

Topics

• Adult
• Angiogenesis Inhibitors (therapeutic use)
• Angioid Streaks (complications)
• Antibodies, Monoclonal (therapeutic use)
• Antibodies, Monoclonal, Humanized
• Bevacizumab
• Choroidal Neovascularization (drug therapy, etiology)
• Choroiditis (complications)
• Drug Therapy, Combination
• Female
• Follow-Up Studies
• Fovea Centralis
• Humans
• Injections
• Macular Degeneration (complications)
• Male
• Middle Aged
• Myopia, Degenerative (complications)
• Photochemotherapy
• Retrospective Studies
• Tomography, Optical Coherence
• Treatment Outcome
• Triamcinolone Acetonide (therapeutic use)
• Vascular Endothelial Growth Factor A (antagonists & inhibitors)
• Visual Acuity
• Vitreous Body